News Search Results
Jul 10, 2026, 09:00 ET Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting
PigmentosaMONTREAL, July 10, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Jul 10, 2026, 04:53 ET Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
address unmet medical needs in this patient population.About Leads BiolabsFounded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology,
More news about: Nanjing Leads Biolabs Co., Ltd.
Jul 09, 2026, 16:15 ET /C O R R E C T I O N -- RyboDyn/
knowledgebaseSAN DIEGO, July 9, 2026 /PRNewswire/ -- RyboDyn, Inc., a biotechnology company decoding the dark proteome with an AI-powered sequencing and discovery platform, today announced a $1.3 million award from the U.S. Department
More news about: RyboDyn
Jul 09, 2026, 13:35 ET Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
securities laws of any such state or other jurisdiction.About Virax Biolabs Group LimitedVirax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling. The Company is developing in vitro diagnostic technologies for viral and
More news about: Virax BioLabs Group Limited
Jul 09, 2026, 13:28 ET EDS, WDS, EBSD Micro-XRF Instruments Market Surges to USD 2.5 Billion by 2033, Propelled by 8.5% CAGR - Verified Market Reports®
CeramicsCompositesMetalsPolymersBy ApplicationSemiconductorsOil and GasPharmaceuticals and BiotechnologyManufacturingBy Product TypeBench-top UnitsHandheld InstrumentsPortable DevicesBy
More news about: Verified Market Reports
Jul 09, 2026, 13:16 ET /C O R R E C T I O N -- Eli Lilly and Company/
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jul 09, 2026, 13:09 ET Stem Cell Banking Market Surges to USD 28.9 Billion by 2033, Propelled by 12.4% CAGR - Verified Market Reports®
government investment in biotechnology infrastructure. China's 14th Five-Year Plan explicitly prioritizes biopharmaceutical and regenerative medicine development, with national stem cell banking registry expansion forming a core component of this strategic agenda. India's biotechnology sector, supported by
More news about: Verified Market Reports
Jul 09, 2026, 10:46 ET Global Pharmacogenomic Testing Service Market to Register Stunning Growth at a CAGR of ~12% by 2034 | DelveInsight
initiatives, including nationwide genome sequencing programs and strategic partnerships among research institutions, healthcare providers, and biotechnology companies, which are facilitating the integration of pharmacogenomic testing into standard clinical care. In addition, the implementation
More news about: DelveInsight Business Research, LLP
Jul 09, 2026, 10:31 ET Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SLE companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio,
More news about: DelveInsight Business Research, LLP
Jul 09, 2026, 10:01 ET B-Cell Depletion Therapy Market to Reach USD 62.6 Billion by 2036, Growing at an 8.9% CAGR as Next-Generation Immunotherapy Adoption Accelerates
programs.Johnson & Johnson — Broad immunology portfolio with global commercialization capabilities.Other regional and emerging biotechnology companies.Competition increasingly centers on improved dosing flexibility, expanded regulatory approvals, real-world clinical evidence,
More news about: Future Market Insights
Jul 09, 2026, 08:37 ET Aureum Therapeutics Announces Successful Prevention of Recurrent Miscarriage using NomiCell™ Stem Cells in Preclinical Studies
SAN DIEGO, July 9, 2026 /PRNewswire/ -- Aureum Therapeutics, a clinical-stage biotechnology company dedicated to developing immunology-based treatments for recurrent miscarriage and cancer, announced today its collaborative publication
More news about: Aureum Therapeutics
Jul 09, 2026, 08:31 ET MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial
More news about: MetaVia Inc.
Jul 09, 2026, 08:30 ET FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
HOUSTON, July 9, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts
More news about: FibroBiologics, Inc.
Jul 09, 2026, 08:18 ET Rocket One Adds SpaceXAI API to Its AI Technology Stack, Advancing Next-Generation Space and Defense Computing
defense and space systems. The Company is also positioned to pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly
More news about: Rocket One Inc.
Jul 09, 2026, 08:00 ET Apertura Gene Therapy Announces Cooperative Research and Development Agreement with Institutes of the NIH to Test Investigational Gene Therapy for Niemann-Pick Disease Type C1
research—NEW YORK, July 9, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced that it has entered into a Cooperative Research
More news about: Apertura Gene Therapy
Jul 09, 2026, 07:30 ET Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
assessing its performance across multiple regional markets."About Virax Biolabs Group LimitedVirax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling. The Company is developing in vitro diagnostic technologies for viral and
More news about: Virax BioLabs Group Limited
Jul 09, 2026, 06:30 ET Immunic to Participate in Investor Conferences in July
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences
More news about: Immunic, Inc.
Jul 09, 2026, 06:01 ET Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer
financing round in 2024. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start‐up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases.
More news about: Blue Earth Therapeutics
Jul 09, 2026, 05:28 ET InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results
More news about: InxMed Co., Ltd
Jul 08, 2026, 21:13 ET HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (MOU) with InxMed (Shanghai) Co., Ltd., a late-stage biotechnology company focused on cancer drug resistance and tumor microenvironment biology.
More news about: HanchorBio Inc.
Jul 08, 2026, 20:30 ET Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
pace toward a next-generation biotechnology platform that combines technological leadership with commercial sustainability.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating
More news about: Insilico Medicine
Jul 08, 2026, 15:00 ET Health Management Associates Names Arda Ural Chief Operating Officer
business unit. At Eyetech Pharmaceuticals Ural served as senior vice president of marketing and sales, building commercial capabilities for the biotechnology company through its initial public offering which led to its acquisition. During his 10 years in leadership roles at Pfizer he led the multi-billion
More news about: Health Management Associates
Jul 08, 2026, 14:42 ET Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
Md., July 8, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the Company's Chief Technical Officer,
More news about: Northwest Biotherapeutics, Inc.
Jul 08, 2026, 14:24 ET Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
Md., July 8, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the Company's Chief Technical Officer, Dr. Marnix
More news about: Northwest Biotherapeutics, Inc.
Jul 08, 2026, 11:54 ET Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
continuous regulatory support for advanced biologics production. Canada contributes through growing vaccine manufacturing capacity and increasing biotechnology partnerships.Asia Pacific is the fastest-growing region, projected to record the highest CAGR through 2033. China continues expanding domestic
More news about: Persistence Market Research Pvt. Ltd.